- The P-III study involves assessing of Lyrica (pregabalin, bid, 5mg/10mg) vs PBO in 219 patients in a ratio (1:1:1) with PGTC seizures aged 5 to 65 yrs. across 21 countries for 12wks.
- The P-III study results demonstrated that it did not meet its 1EPs i.e, reduction in seizure frequency
- Lyrica (pregabalin) is a chemical analog of Gabapentin and is an approved therapy for multiple indications for both adults & pediatric patients across 130 countries including the US
Click here to read full press release/ article | Ref: Pfizer | Image: Total Ventures